Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Autoimmune Disorders

  Free Subscription


Articles published in J Neurol

Retrieve available abstracts of 129 articles:
HTML format
Text format



Single Articles


    December 2018
  1. JOHNEN A, Burkner PC, Landmeyer NC, Ambrosius B, et al
    Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).
    J Neurol. 2018 Dec 4. pii: 10.1007/s00415-018-9142.
    PubMed     Text format     Abstract available


    November 2018
  2. MEGNA R, Alfano B, Lanzillo R, Costabile T, et al
    Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment.
    J Neurol. 2018 Nov 29. pii: 10.1007/s00415-018-9139.
    PubMed     Text format     Abstract available


  3. KILJAN S, Meijer KA, Steenwijk MD, Pouwels PJW, et al
    Structural network topology relates to tissue properties in multiple sclerosis.
    J Neurol. 2018 Nov 22. pii: 10.1007/s00415-018-9130.
    PubMed     Text format     Abstract available


  4. HARDING KE, Robertson NP
    New rare genetic variants in multiple sclerosis.
    J Neurol. 2018 Nov 20. pii: 10.1007/s00415-018-9128.
    PubMed     Text format    


  5. RIEDERER I, Muhlau M, Hoshi MM, Zimmer C, et al
    Detecting optic nerve lesions in clinically isolated syndrome and multiple sclerosis: double-inversion recovery magnetic resonance imaging in comparison with visually evoked potentials.
    J Neurol. 2018 Nov 16. pii: 10.1007/s00415-018-9114.
    PubMed     Text format     Abstract available


  6. BAUMGARTNER A, Rauer S, Hottenrott T, Leypoldt F, et al
    Admission diagnoses of patients later diagnosed with autoimmune encephalitis.
    J Neurol. 2018 Nov 12. pii: 10.1007/s00415-018-9105.
    PubMed     Text format     Abstract available


  7. SAEZ MS, Rojas JI, Lorenzon MV, Sanchez F, et al
    Validation of CSF free light chain in diagnosis and prognosis of multiple sclerosis and clinically isolated syndrome: prospective cohort study in Buenos Aires.
    J Neurol. 2018 Nov 1. pii: 10.1007/s00415-018-9106.
    PubMed     Text format     Abstract available


    October 2018
  8. ELLRICHMANN G, Bolz J, Peschke M, Duscha A, et al
    Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders.
    J Neurol. 2018 Oct 30. pii: 10.1007/s00415-018-9092.
    PubMed     Text format     Abstract available


  9. MCLAUGHLIN L, Clarke L, Khalilidehkordi E, Butzkueven H, et al
    Vitamin D for the treatment of multiple sclerosis: a meta-analysis.
    J Neurol. 2018 Oct 3. pii: 10.1007/s00415-018-9074.
    PubMed     Text format     Abstract available


  10. TOMMASIN S, De Giglio L, Ruggieri S, Petsas N, et al
    Relation between functional connectivity and disability in multiple sclerosis: a non-linear model.
    J Neurol. 2018 Oct 1. pii: 10.1007/s00415-018-9075.
    PubMed     Text format     Abstract available


    September 2018
  11. PROSPERINI L, Annovazzi P, Boffa L, Buscarinu MC, et al
    No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
    J Neurol. 2018 Sep 26. pii: 10.1007/s00415-018-9070.
    PubMed     Text format     Abstract available


  12. TUDOR KI, Eames S, Haslam C, Chataway J, et al
    Identifying barriers to help-seeking for sexual dysfunction in multiple sclerosis.
    J Neurol. 2018 Sep 19. pii: 10.1007/s00415-018-9064.
    PubMed     Text format     Abstract available


  13. LI F, Hotter B, Swierzy M, Ismail M, et al
    Generalization after ocular onset in myasthenia gravis: a case series in Germany.
    J Neurol. 2018 Sep 17. pii: 10.1007/s00415-018-9056.
    PubMed     Text format     Abstract available


  14. FAKIH R, Matiello M, Chitnis T, Stankiewicz JM, et al
    Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients.
    J Neurol. 2018 Sep 10. pii: 10.1007/s00415-018-9050.
    PubMed     Text format     Abstract available


  15. GAETANI L, Prosperini L, Mancini A, Eusebi P, et al
    2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes.
    J Neurol. 2018 Sep 8. pii: 10.1007/s00415-018-9048.
    PubMed     Text format     Abstract available


  16. LY LT, Kreye J, Jurek B, Leubner J, et al
    Affinities of human NMDA receptor autoantibodies: implications for disease mechanisms and clinical diagnostics.
    J Neurol. 2018 Sep 5. pii: 10.1007/s00415-018-9042.
    PubMed     Text format     Abstract available


  17. CAMBRON M, Reynders T, Debruyne J, Reyngoudt H, et al
    Targeting phosphocreatine metabolism in relapsing-remitting multiple sclerosis: evaluation with brain MRI, (1)H and (31)P MRS, and clinical and cognitive testing.
    J Neurol. 2018 Sep 5. pii: 10.1007/s00415-018-9039.
    PubMed     Text format     Abstract available


  18. VAN LIEVERLOO GGA, Peric S, Doneddu PE, Gallia F, et al
    Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone.
    J Neurol. 2018;265:2052-2059.
    PubMed     Text format     Abstract available


    August 2018
  19. FILSER M, Schreiber H, Pottgen J, Ullrich S, et al
    The Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS): results from the German validation study.
    J Neurol. 2018 Aug 31. pii: 10.1007/s00415-018-9034.
    PubMed     Text format     Abstract available


  20. BABER U, Bouley A, Egnor E, Sloane JA, et al
    Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients.
    J Neurol. 2018 Aug 14. pii: 10.1007/s00415-018-8996.
    PubMed     Text format     Abstract available


  21. ALEKSEEVA TM, Gavrilov YV, Kreis OA, Valko PO, et al
    Fatigue in patients with myasthenia gravis.
    J Neurol. 2018 Aug 11. pii: 10.1007/s00415-018-8995.
    PubMed     Text format     Abstract available


  22. RUMPF JJ, Dietrich S, Stoppe M, Fricke C, et al
    Compromised tDCS-induced facilitation of motor consolidation in patients with multiple sclerosis.
    J Neurol. 2018 Aug 6. pii: 10.1007/s00415-018-8993.
    PubMed     Text format     Abstract available


  23. SEITZ CB, Droby A, Zaubitzer L, Kramer J, et al
    Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging.
    J Neurol. 2018 Aug 2. pii: 10.1007/s00415-018-8988.
    PubMed     Text format     Abstract available


  24. MALLUCCI G, Annovazzi P, Miante S, Torri-Clerici V, et al
    Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study.
    J Neurol. 2018;265:1850-1859.
    PubMed     Text format     Abstract available


  25. CAO D, Guo X, Yuan T, Hao J, et al
    Diagnosing chronic inflammatory demyelinating polyradiculoneuropathy with triple stimulation technique.
    J Neurol. 2018;265:1916-1921.
    PubMed     Text format     Abstract available


    July 2018
  26. FROHLICH K, Winder K, Linker RA, Huhn K, et al
    Lesion correlates of secondary paroxysmal dyskinesia in multiple sclerosis.
    J Neurol. 2018 Jul 31. pii: 10.1007/s00415-018-8989.
    PubMed     Text format     Abstract available


  27. COCOZZA S, Pontillo G, Russo C, Russo CV, et al
    Cerebellum and cognition in progressive MS patients: functional changes beyond atrophy?
    J Neurol. 2018 Jul 28. pii: 10.1007/s00415-018-8985.
    PubMed     Text format     Abstract available


  28. BALLOY G, Pelletier J, Suchet L, Lebrun C, et al
    Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.
    J Neurol. 2018 Jul 27. pii: 10.1007/s00415-018-8984.
    PubMed     Text format     Abstract available


  29. BARONE S, Caligiuri ME, Valentino P, Cherubini A, et al
    Multimodal assessment of normal-appearing corpus callosum is a useful marker of disability in relapsing-remitting multiple sclerosis: an MRI cluster analysis study.
    J Neurol. 2018 Jul 26. pii: 10.1007/s00415-018-8980.
    PubMed     Text format     Abstract available


  30. GALGANI S, Prosperini L, Haggiag S, Tortorella C, et al
    Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case report.
    J Neurol. 2018 Jul 17. pii: 10.1007/s00415-018-8976.
    PubMed     Text format    


  31. BOST C, Chanson E, Picard G, Meyronet D, et al
    Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies.
    J Neurol. 2018 Jul 12. pii: 10.1007/s00415-018-8970.
    PubMed     Text format     Abstract available


  32. ALADRO Y, Lopez-Alvarez L, Sanchez-Reyes JM, Hernandez-Tamames JA, et al
    Relationship between episodic memory and volume of the brain regions of two functional cortical memory systems in multiple sclerosis.
    J Neurol. 2018 Jul 11. pii: 10.1007/s00415-018-8965.
    PubMed     Text format     Abstract available


  33. KALLWEIT U, Bassetti CLA, Oberholzer M, Fronczek R, et al
    Coexisting narcolepsy (with and without cataplexy) and multiple sclerosis : Six new cases and a literature review.
    J Neurol. 2018 Jul 4. pii: 10.1007/s00415-018-8949.
    PubMed     Text format     Abstract available


    June 2018
  34. BAJRAMI A, Pitteri M, Castellaro M, Pizzini F, et al
    The effect of fingolimod on focal and diffuse grey matter damage in active MS patients.
    J Neurol. 2018 Jun 25. pii: 10.1007/s00415-018-8952.
    PubMed     Text format     Abstract available


  35. MOTTE J, Kneiphof J, Strassburger-Krogias K, Klasing A, et al
    Detection of JC virus archetype in cerebrospinal fluid in a MS patient with dimethylfumarate treatment without lymphopenia or signs of PML.
    J Neurol. 2018 Jun 15. pii: 10.1007/s00415-018-8931.
    PubMed     Text format     Abstract available


    May 2018
  36. MARSHALL I, Thrippleton MJ, Bastin ME, Mollison D, et al
    Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study.
    J Neurol. 2018 May 30. pii: 10.1007/s00415-018-8903.
    PubMed     Text format     Abstract available


  37. YAMAGUCHI H, Sakai K, Goto Y, Yamada M, et al
    Autoimmune hepatitis induced by a single injection of interferon-beta 1a in a patient with multiple sclerosis.
    J Neurol. 2018 May 29. pii: 10.1007/s00415-018-8912.
    PubMed     Text format    


  38. SANTANGELO G, Bisecco A, Trojano L, Sacco R, et al
    Cognitive performance in multiple sclerosis: the contribution of intellectual enrichment and brain MRI measures.
    J Neurol. 2018 May 26. pii: 10.1007/s00415-018-8905.
    PubMed     Text format     Abstract available


  39. ALCALA C, Gascon F, Perez-Miralles F, Gil-Perotin S, et al
    Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study.
    J Neurol. 2018 May 21. pii: 10.1007/s00415-018-8899.
    PubMed     Text format     Abstract available


  40. KOCSIK AS, Klein DE, Liedke M, Kaunzner UW, et al
    Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.
    J Neurol. 2018;265:1226-1229.
    PubMed     Text format     Abstract available


  41. OPFER R, Ostwaldt AC, Walker-Egger C, Manogaran P, et al
    Within-patient fluctuation of brain volume estimates from short-term repeated MRI measurements using SIENA/FSL.
    J Neurol. 2018;265:1158-1165.
    PubMed     Text format     Abstract available


  42. TALLANTYRE EC, Whittam DH, Jolles S, Paling D, et al
    Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation.
    J Neurol. 2018;265:1115-1122.
    PubMed     Text format     Abstract available


    April 2018
  43. RASUL T, Frederiksen JL
    Link between overweight/obese in children and youngsters and occurrence of multiple sclerosis.
    J Neurol. 2018 Apr 26. pii: 10.1007/s00415-018-8869.
    PubMed     Text format     Abstract available


  44. HUHN K, Bayas A, Doerck S, Frank B, et al
    Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
    J Neurol. 2018 Apr 25. pii: 10.1007/s00415-018-8871.
    PubMed     Text format     Abstract available


  45. TAVAZZI E, Bergsland N, Cattaneo D, Gervasoni E, et al
    Effects of motor rehabilitation on mobility and brain plasticity in multiple sclerosis: a structural and functional MRI study.
    J Neurol. 2018 Apr 7. pii: 10.1007/s00415-018-8859.
    PubMed     Text format     Abstract available


  46. CABRE P, Mejdoubi M, Jeannin S, Merle H, et al
    Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study.
    J Neurol. 2018;265:917-925.
    PubMed     Text format     Abstract available


    March 2018
  47. COGHE G, Corona F, Marongiu E, Fenu G, et al
    Fatigue, as measured using the Modified Fatigue Impact Scale, is a predictor of processing speed improvement induced by exercise in patients with multiple sclerosis: data from a randomized controlled trial.
    J Neurol. 2018 Mar 24. pii: 10.1007/s00415-018-8836.
    PubMed     Text format     Abstract available


  48. NAKKEN O, Lindstrom JC, Holmoy T
    Sex ratio in multiple sclerosis mortality over 65 years; an age-period-cohort analysis in Norway.
    J Neurol. 2018 Mar 21. pii: 10.1007/s00415-018-8832.
    PubMed     Text format     Abstract available


  49. CERONIE B, Jacobs BM, Baker D, Dubuisson N, et al
    Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.
    J Neurol. 2018 Mar 17. pii: 10.1007/s00415-018-8830.
    PubMed     Text format     Abstract available


  50. LANZILLO R, Prosperini L, Gasperini C, Moccia M, et al
    A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.
    J Neurol. 2018 Mar 16. pii: 10.1007/s00415-018-8831.
    PubMed     Text format     Abstract available


  51. AOYAMA S, Mori M, Uzawa A, Uchida T, et al
    Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration.
    J Neurol. 2018 Mar 12. pii: 10.1007/s00415-018-8813.
    PubMed     Text format     Abstract available


  52. DEVONSHIRE V, Phillips R, Wass H, Da Roza G, et al
    Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
    J Neurol. 2018 Mar 10. pii: 10.1007/s00415-018-8822.
    PubMed     Text format     Abstract available


  53. HOTTENROTT T, Schorb E, Fritsch K, Dersch R, et al
    The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis.
    J Neurol. 2018 Mar 6. pii: 10.1007/s00415-018-8779.
    PubMed     Text format     Abstract available


  54. LOREFICE L, Fenu G, Pitzalis R, Scalas G, et al
    Autoimmune comorbidities in multiple sclerosis: what is the influence on brain volumes? A case-control MRI study.
    J Neurol. 2018 Mar 5. pii: 10.1007/s00415-018-8811.
    PubMed     Text format     Abstract available


  55. KANEKO A, Kaneko J, Tominaga N, Kanazawa N, et al
    Pitfalls in clinical diagnosis of anti-NMDA receptor encephalitis.
    J Neurol. 2018;265:586-596.
    PubMed     Text format     Abstract available


    February 2018
  56. BROICHER SD, Filli L, Geisseler O, Germann N, et al
    Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.
    J Neurol. 2018 Feb 20. pii: 10.1007/s00415-018-8796.
    PubMed     Text format     Abstract available


  57. VAN DER VUURST DE VRIES RM, Mescheriakova JY, Runia TF, Siepman TAM, et al
    Smoking at time of CIS increases the risk of clinically definite multiple sclerosis.
    J Neurol. 2018 Feb 20. pii: 10.1007/s00415-018-8780.
    PubMed     Text format     Abstract available


  58. BELL JS, Spencer JI, Yates RL, DeLuca GC, et al
    The cortical blood-brain barrier in multiple sclerosis: a gateway to progression?
    J Neurol. 2018 Feb 13. pii: 10.1007/s00415-017-8727.
    PubMed     Text format    


  59. ESPOSITO F, Ferre L, Clarelli F, Rocca MA, et al
    Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.
    J Neurol. 2018 Feb 12. pii: 10.1007/s00415-018-8791.
    PubMed     Text format     Abstract available


  60. ARNETH B
    Up-to-date knowledge about the association between multiple sclerosis and the reactivation of human endogenous retrovirus infections.
    J Neurol. 2018 Feb 8. pii: 10.1007/s00415-018-8783.
    PubMed     Text format     Abstract available


  61. SOLARO C, Cella M, Signori A, Martinelli V, et al
    Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria.
    J Neurol. 2018 Feb 5. pii: 10.1007/s00415-018-8758.
    PubMed     Text format     Abstract available


  62. KALRON A, Allali G, Achiron A
    Cerebellum and cognition in multiple sclerosis: the fall status matters.
    J Neurol. 2018 Feb 2. pii: 10.1007/s00415-018-8774.
    PubMed     Text format     Abstract available


  63. WINDER K, Linker RA, Seifert F, Deutsch M, et al
    Insular multiple sclerosis lesions are associated with erectile dysfunction.
    J Neurol. 2018 Feb 1. pii: 10.1007/s00415-018-8763.
    PubMed     Text format     Abstract available


  64. LANDFELDT E, Castelo-Branco A, Svedbom A, Lofroth E, et al
    The long-term impact of early treatment of multiple sclerosis on the risk of disability pension.
    J Neurol. 2018 Feb 1. pii: 10.1007/s00415-018-8764.
    PubMed     Text format     Abstract available


  65. FRAU J, Carai M, Coghe G, Fenu G, et al
    Long-term follow-up more than 10 years after HSCT: a monocentric experience.
    J Neurol. 2018;265:410-416.
    PubMed     Text format     Abstract available


  66. AKDAL G, Tanriverdizade T, Sengun I, Bademkiran F, et al
    Vestibular impairment in chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2018;265:381-387.
    PubMed     Text format     Abstract available


  67. WANG R, Lai XH, Liu X, Li YJ, et al
    Brain magnetic resonance-imaging findings of anti-N-methyl-D-aspartate receptor encephalitis: a cohort follow-up study in Chinese patients.
    J Neurol. 2018;265:362-369.
    PubMed     Text format     Abstract available


  68. HONGELL K, Silva DG, Ritter S, Meier DP, et al
    Efficacy and safety outcomes in vitamin D supplement users in the fingolimod phase 3 trials.
    J Neurol. 2018;265:348-355.
    PubMed     Text format     Abstract available


    January 2018
  69. VOGRIG A, Joubert B, Ducray F, Thomas L, et al
    Glioblastoma as differential diagnosis of autoimmune encephalitis.
    J Neurol. 2018 Jan 30. pii: 10.1007/s00415-018-8767.
    PubMed     Text format     Abstract available


  70. GILHUS NE, Romi F, Hong Y, Skeie GO, et al
    Myasthenia gravis and infectious disease.
    J Neurol. 2018 Jan 25. pii: 10.1007/s00415-018-8751.
    PubMed     Text format     Abstract available


  71. FIENE M, Rufener KS, Kuehne M, Matzke M, et al
    Electrophysiological and behavioral effects of frontal transcranial direct current stimulation on cognitive fatigue in multiple sclerosis.
    J Neurol. 2018 Jan 22. pii: 10.1007/s00415-018-8754.
    PubMed     Text format     Abstract available


  72. LEAVITT VM, Tosto G, Riley CS
    Cognitive phenotypes in multiple sclerosis.
    J Neurol. 2018 Jan 22. pii: 10.1007/s00415-018-8747.
    PubMed     Text format     Abstract available


  73. DI GREGORIO M, Gaetani L, Eusebi P, Floridi P, et al
    Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes.
    J Neurol. 2018 Jan 11. pii: 10.1007/s00415-017-8726.
    PubMed     Text format     Abstract available


  74. MCMACKEN G, Whittaker RG, Evangelista T, Abicht A, et al
    Congenital myasthenic syndrome with episodic apnoea: clinical, neurophysiological and genetic features in the long-term follow-up of 19 patients.
    J Neurol. 2018;265:194-203.
    PubMed     Text format     Abstract available


  75. ALENDA R, Costa-Frossard L, Alvarez-Lafuente R, Espejo C, et al
    Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.
    J Neurol. 2018;265:24-31.
    PubMed     Text format     Abstract available


    December 2017
  76. FRAU J, Villar LM, Sardu C, Secci MA, et al
    Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?
    J Neurol. 2017 Dec 22. pii: 10.1007/s00415-017-8716.
    PubMed     Text format     Abstract available


  77. BRENTON JN, Schreiner T, Karoscik K, Richter M, et al
    Attitudes, perceptions, and use of marijuana in youth with multiple sclerosis.
    J Neurol. 2017 Dec 22. pii: 10.1007/s00415-017-8715.
    PubMed     Text format     Abstract available


  78. SHRIBMAN S, Hasan H, Hadavi S, Giovannoni G, et al
    The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis.
    J Neurol. 2017 Dec 4. pii: 10.1007/s00415-017-8690.
    PubMed     Text format     Abstract available


    November 2017
  79. THALER C, Faizy TD, Sedlacik J, Bester M, et al
    The use of multiparametric quantitative magnetic resonance imaging for evaluating visually assigned lesion groups in patients with multiple sclerosis.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8683.
    PubMed     Text format     Abstract available


  80. CONRADSSON D, Ytterberg C, von Koch L, Johansson S, et al
    Changes in disability in people with multiple sclerosis: a 10-year prospective study.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8676.
    PubMed     Text format     Abstract available


  81. ELIASDOTTIR O, Hildeman A, Longfils M, Nerman O, et al
    A nationwide survey of the influence of month of birth on the risk of developing multiple sclerosis in Sweden and Iceland.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8665.
    PubMed     Text format     Abstract available


  82. RUPRECHT K, Wildemann B, Jarius S
    Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature.
    J Neurol. 2017 Nov 2. doi: 10.1007/s00415-017-8656.
    PubMed     Text format     Abstract available


    October 2017
  83. COMI G, Patti F, Rocca MA, Mattioli FC, et al
    Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
    J Neurol. 2017 Oct 23. doi: 10.1007/s00415-017-8642.
    PubMed     Text format     Abstract available


  84. PARDO G, Jones DE
    Correction to: The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
    J Neurol. 2017 Oct 23. doi: 10.1007/s00415-017-8633.
    PubMed     Text format     Abstract available


  85. ABBOUD H, Rossman I, Mealy MA, Hill E, et al
    Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results.
    J Neurol. 2017 Oct 3. doi: 10.1007/s00415-017-8627.
    PubMed     Text format     Abstract available


    September 2017
  86. WANG L, Zhang S, Xi J, Li W, et al
    Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis.
    J Neurol. 2017 Sep 18. doi: 10.1007/s00415-017-8616.
    PubMed     Text format     Abstract available


  87. LOREFICE L, Coghe G, Fenu G, Porta M, et al
    'Timed up and go' and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis.
    J Neurol. 2017 Sep 11. doi: 10.1007/s00415-017-8612.
    PubMed     Text format     Abstract available


  88. PARDO G, Jones DE
    The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
    J Neurol. 2017 Sep 6. doi: 10.1007/s00415-017-8594.
    PubMed     Text format     Abstract available


    August 2017
  89. LATTANZI S, Danni M, Taffi R, Cerqua R, et al
    Persistence to oral disease-modifying therapies in multiple sclerosis patients.
    J Neurol. 2017 Aug 22. doi: 10.1007/s00415-017-8595.
    PubMed     Text format     Abstract available


  90. HRASTELJ J, Robertson N
    Genetics of disease severity in multiple sclerosis, Alzheimer's disease, and Huntington's disease: rejuvenating genome-wide association studies.
    J Neurol. 2017 Aug 7. doi: 10.1007/s00415-017-8584.
    PubMed     Text format    


  91. FINKE C, Bartels F, Lutt A, Pruss H, et al
    High prevalence of neuronal surface autoantibodies associated with cognitive deficits in cancer patients.
    J Neurol. 2017 Aug 7. doi: 10.1007/s00415-017-8582.
    PubMed     Text format     Abstract available


    July 2017
  92. EICHINGER P, Wiestler H, Zhang H, Biberacher V, et al
    A novel imaging technique for better detecting new lesions in multiple sclerosis.
    J Neurol. 2017 Jul 29. doi: 10.1007/s00415-017-8576.
    PubMed     Text format     Abstract available


  93. SCHOSER B, Eymard B, Datt J, Mantegazza R, et al
    Erratum to: Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
    J Neurol. 2017 Jul 10. doi: 10.1007/s00415-017-8556.
    PubMed     Text format    


    June 2017
  94. CASEY JP, Hirouchi T, Hisatsune C, Lynch B, et al
    A novel gain-of-function mutation in the ITPR1 suppressor domain causes spinocerebellar ataxia with altered Ca2+ signal patterns.
    J Neurol. 2017 Jun 15. doi: 10.1007/s00415-017-8545.
    PubMed     Text format     Abstract available


  95. SCHOSER B, Eymard B, Datt J, Mantegazza R, et al
    Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
    J Neurol. 2017 Jun 12. doi: 10.1007/s00415-017-8541.
    PubMed     Text format     Abstract available


  96. HAGSTROM IT, Schneider R, Bellenberg B, Salmen A, et al
    Relevance of early cervical cord volume loss in the disease evolution of clinically isolated syndrome and early multiple sclerosis: a 2-year follow-up study.
    J Neurol. 2017 Jun 9. doi: 10.1007/s00415-017-8537.
    PubMed     Text format     Abstract available


    May 2017
  97. BRITZE J, Pihl-Jensen G, Frederiksen JL
    Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis.
    J Neurol. 2017 May 31. doi: 10.1007/s00415-017-8531.
    PubMed     Text format     Abstract available


  98. DIBLEY L, Coggrave M, McClurg D, Woodward S, et al
    "It's just horrible": a qualitative study of patients' and carers' experiences of bowel dysfunction in multiple sclerosis.
    J Neurol. 2017 May 26. doi: 10.1007/s00415-017-8527.
    PubMed     Text format     Abstract available


  99. RATH J, Mauritz M, Zulehner G, Hilger E, et al
    Iodinated contrast agents in patients with myasthenia gravis: a retrospective cohort study.
    J Neurol. 2017 May 26. doi: 10.1007/s00415-017-8518.
    PubMed     Text format     Abstract available


  100. RIVIERE E, Cohen Aubart F, Maisonobe T, Maurier F, et al
    Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study.
    J Neurol. 2017 May 23. doi: 10.1007/s00415-017-8519.
    PubMed     Text format     Abstract available


  101. FOULON S, Maura G, Dalichampt M, Alla F, et al
    Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data.
    J Neurol. 2017 May 17. doi: 10.1007/s00415-017-8513.
    PubMed     Text format     Abstract available


  102. CORDTS I, Bodart N, Hartmann K, Karagiorgou K, et al
    Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis.
    J Neurol. 2017 May 17. doi: 10.1007/s00415-017-8514.
    PubMed     Text format     Abstract available


  103. LATTANZI S, Cagnetti C, Danni M, Provinciali L, et al
    Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis.
    J Neurol. 2017 May 10. doi: 10.1007/s00415-017-8505.
    PubMed     Text format     Abstract available


    April 2017
  104. HARDING K, Tilling K, MacIver C, Willis M, et al
    Seasonal variation in multiple sclerosis relapse.
    J Neurol. 2017 Apr 19. doi: 10.1007/s00415-017-8485.
    PubMed     Text format     Abstract available


  105. SARTORI A, Abdoli M, Freedman MS
    Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study.
    J Neurol. 2017 Apr 17. doi: 10.1007/s00415-017-8487.
    PubMed     Text format     Abstract available


  106. HAINLINE C, Rizzo JR, Hudson TE, Dai W, et al
    Capturing saccades in multiple sclerosis with a digitized test of rapid number naming.
    J Neurol. 2017 Apr 7. doi: 10.1007/s00415-017-8484.
    PubMed     Text format     Abstract available


  107. CHOI HA, Lee MJ, Chung CS
    Characteristics of hypertrophic pachymeningitis in patients with granulomatosis with polyangiitis.
    J Neurol. 2017;264:724-732.
    PubMed     Text format     Abstract available


  108. BARTOLINI L, Muscal E
    Differences in treatment of anti-NMDA receptor encephalitis: results of a worldwide survey.
    J Neurol. 2017;264:647-653.
    PubMed     Text format     Abstract available


    March 2017
  109. HONG Y, Skeie GO, Zisimopoulou P, Karagiorgou K, et al
    Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms.
    J Neurol. 2017 Mar 31. doi: 10.1007/s00415-017-8478.
    PubMed     Text format     Abstract available


  110. PREZIOSA P, Martinelli V, Ferre L, Guaschino C, et al
    Moyamoya disease mimicking the first attack of multiple sclerosis.
    J Neurol. 2017 Mar 17. doi: 10.1007/s00415-017-8458.
    PubMed     Text format    


  111. KHAN F, Amatya B, Galea MP, Gonzenbach R, et al
    Neurorehabilitation: applied neuroplasticity.
    J Neurol. 2017;264:603-615.
    PubMed     Text format     Abstract available


    February 2017
  112. MALONEY E, Molloy A, Al Hussona M, O'Donnell L, et al
    Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.
    J Neurol. 2017;264:401-403.
    PubMed     Text format    


    January 2017
  113. BIANCHI A, Bartolini E, Melani F, Guerrini R, et al
    Isolated recurrent myelitis in a 7-year-old child with serum aquaporin-4 IgG antibodies.
    J Neurol. 2017;264:179-181.
    PubMed     Text format    


    December 2016
  114. GIORLI E, Franciotta D, Beronio A, Amodeo C, et al
    Late AQP4-IgG seroconversion and shrinking of brainstem MRI lesions in a patient with overlapping CIS/NMOSD.
    J Neurol. 2016;263:2549-2551.
    PubMed     Text format    


  115. HUSS AM, Halbgebauer S, Ockl P, Trebst C, et al
    Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome.
    J Neurol. 2016;263:2499-2504.
    PubMed     Text format     Abstract available


  116. HUANG Q, Wu Y, Qin R, Wei X, et al
    Clinical characteristics and outcomes between children and adults with anti-N-Methyl-D-Aspartate receptor encephalitis.
    J Neurol. 2016;263:2446-2455.
    PubMed     Text format     Abstract available


    October 2016
  117. PIETRZAK K, Grzybowski A, Kaczmarczyk J
    Georges Guillain (1876-1961).
    J Neurol. 2016;263:2148-9.
    PubMed     Text format    


  118. ABSINTA M, Reich DS, Filippi M
    Spring cleaning: time to rethink imaging research lines in MS?
    J Neurol. 2016;263:1893-902.
    PubMed     Text format     Abstract available


    September 2016
  119. MAILLART E, Papeix C, Mellerio C, Bertrand A, et al
    Extensive and severe CNS demyelination associated with golimumab therapy.
    J Neurol. 2016;263:1869-71.
    PubMed     Text format    


  120. LOZERON P, Ribrag V, Adams D, Brisset M, et al
    Is distal motor and/or sensory demyelination a distinctive feature of anti-MAG neuropathy?
    J Neurol. 2016;263:1761-70.
    PubMed     Text format     Abstract available


  121. ANNOVAZZI P, Capobianco M, Moiola L, Patti F, et al
    Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.
    J Neurol. 2016;263:1727-35.
    PubMed     Text format     Abstract available


    August 2016
  122. ZURAWSKI J, Flinn A, Sklover L, Sloane JA, et al
    Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.
    J Neurol. 2016;263:1511-7.
    PubMed     Text format     Abstract available


    July 2016
  123. ZHOU H, Zhao S, Yin D, Chen X, et al
    Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages.
    J Neurol. 2016;263:1382-9.
    PubMed     Text format     Abstract available


  124. JEONG IH, Kim HJ, Kim NH, Jeong KS, et al
    Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder.
    J Neurol. 2016;263:1343-8.
    PubMed     Text format     Abstract available


  125. BALK LJ, Cruz-Herranz A, Albrecht P, Arnow S, et al
    Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study.
    J Neurol. 2016;263:1323-31.
    PubMed     Text format     Abstract available


  126. HAVRDOVA E, Belova A, Goloborodko A, Tisserant A, et al
    Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.
    J Neurol. 2016;263:1287-95.
    PubMed     Text format     Abstract available


    June 2016
  127. BRIER MR, Day GS, Snyder AZ, Tanenbaum AB, et al
    N-methyl-D-aspartate receptor encephalitis mediates loss of intrinsic activity measured by functional MRI.
    J Neurol. 2016;263:1083-91.
    PubMed     Text format     Abstract available


  128. GRIMM A, Vittore D, Schubert V, Rasenack M, et al
    Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP.
    J Neurol. 2016;263:1074-82.
    PubMed     Text format     Abstract available


    May 2016
  129. VINJAM MR, Shanmugarajah P, Ford HL
    Ophthalmoplegia heralding the onset of anti-amphiphysin related paraneoplastic stiff person syndrome.
    J Neurol. 2016;263:1017-8.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: